New pill aims to delay dialysis and save hearts in kidney patients

NCT ID NCT07625774

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This large Phase 3 study tests whether the drug HRS-7535 can help people with chronic kidney disease (CKD) avoid serious outcomes like kidney failure, dialysis, or heart-related death. About 3690 adults with CKD will receive either the drug or a placebo, added to their usual care. The goal is to see if HRS-7535 slows kidney decline and lowers cardiovascular risks over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310003, China

    Contact

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, 300052, China

    Contact